Search results
Results from the WOW.Com Content Network
AbbVie (NYSE: ABBV) closed out a pivotal 2024 with an excellent fourth-quarter earnings report. For the period ended Dec. 31, the biopharmaceuticals giant delivered 6% sales growth and $2.12 in ...
Pharmaceutical powerhouse AbbVie (NYSE: ABBV) has been a beast since it spun off from Abbott Laboratories in 2012. Over the past decade, the stock has averaged a dividend yield of 3.5% while ...
For reference, AbbVie's trailing 12-month revenue was $55.3 billion, so the growth of Skyrizi and Rinvoq represents a major addition to the top line that'll likely drive the stock upwards for ...
The selloff in ABBV stock was always a bit overdramatic. The pharma has over 90 therapies under development, over half of them being in mid- to late-stage trials. AbbVie spent $12.8 billion on ...
Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t ...
Before you buy stock in AbbVie, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and AbbVie wasn’t ...
The contrast between AbbVie's performance and that of the wider market was stark, as the bellwether S&P 500 (SNPINDEX: ^GSPC) sank by a relatively steep 1.5%. Why AbbVie Stock Popped While the ...
AbbVie (NYSE: ABBV) recently dipped nearly 20% and is still down 14%, offering an enticing 3.7% forward yield. Here's what makes AbbVie a long-term buy-and-hold dividend gold mine.